Patents by Inventor David R. Elmaleh

David R. Elmaleh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapies for the treatment of alzheimer's disease and related disorders
    Patent number: 9913847
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: March 13, 2018
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • Methods for delivering cromolyn
    Patent number: 9861608
    Abstract: Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and blister packs and kits comprising cromolyn are described.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: January 9, 2018
    Assignee: AZTHERAPIES, INC
    Inventors: David R. Elmaleh, Alex Franzusoff
  • Combination therapies for the treatment of Alzheimer's disease and related disorders
    Patent number: 9855276
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: January 2, 2018
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • F-18 LABELED TRACER AND METHODS OF MANUFACTURE
    Publication number: 20170334804
    Abstract: A method of producing a radiofluorinated compound comprising the steps of forming a reaction mixture comprising a reactant having a formula of R—Y and a radiofluorinating agent having a formula of R?—18F; and contacting the reaction mixture with microwave radiation to achieve a temperature of between 100° C. and 250° C. for a time sufficient to convert at least 10% of the reactant into the radiofluorinated compound having a formula of R—18F, wherein R is selected from the group consisting of an alkyl (C1-C20), a cycloalkyl (C3-C10), an aryl, a heteroaryl, an aralkyl and an alkenyl group (C2-C20); Y is selected from the group consisting of a sulfonate, a nitro, an acetate and a halogen; and R? is selected from the group consisting of an alkali metal cation, an alkaline earth metal cation, a transition metal cation, an ammonium cation, and a tetraalkylammonium cation is provided.
    Type: Application
    Filed: October 30, 2015
    Publication date: November 23, 2017
    Inventors: David R. Elmaleh, Timothy m. Shoup
  • BIOTIN COMPLEXES FOR TREATMENT AND DIAGNOSIS OF ALZHEIMER'S DISEASE
    Publication number: 20170326244
    Abstract: Described herein are compositions and methods for treating or imaging Alzheimer's disease (AD). The compositions comprise a biotin moiety and a siRNA moiety, without the need for a targeting agent such as an antibody, avidin, or streptavidin. In certain embodiments, the compositions further comprise a diagnostic agent.
    Type: Application
    Filed: May 22, 2017
    Publication date: November 16, 2017
    Inventor: David R. Elmaleh
  • COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS
    Publication number: 20170290797
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Application
    Filed: November 23, 2016
    Publication date: October 12, 2017
    Inventor: David R. Elmaleh
  • ANTICOAGULANT DERIVATIVES FOR CARDIOVASCULAR IMAGING
    Publication number: 20170290931
    Abstract: The invention provides cardiovascular imaging agents comprising an anticoagulant (e.g., dabigatran derivatives) with a label (e.g., radiolabeled, fluorinated or radiofluorinated). Methods for using the cardiovascular imaging agents and kits containing the cardiovascular imaging agents or components suitable for production of the cardiovascular imaging agents are also provided.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Inventor: DAVID R ELMALEH
  • Apparatus and method for detecting and\or monitoring one or more compounds in blood
    Patent number: 9675284
    Abstract: A platform has microneedles for determining blood levels of compound of interest, such as glucose.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: June 13, 2017
    Inventor: David R. Elmaleh
  • Biotin complexes for treatment and diagnosis of alzheimer's disease
    Patent number: 9655977
    Abstract: Described herein are compositions and methods for treating or imaging Alzheimer's disease (AD). The compositions comprise a biotin moiety and a siRNA moiety, without the need for a targeting agent such as an antibody, avidin, or streptavidin. In certain embodiments, the compositions further comprise a diagnostic agent.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: May 23, 2017
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • System and method for access over a cable television network
    Patent number: 9503899
    Abstract: A system and method for allowing a computing device to associate wirelessly with one or more access points that are connected to a cable TV network when such device is in a range of such access point, even though such wireless device would not generally be authorized to receive content or data from the access point. Signals to and from the wireless device are carried over the cable TV network and transmitted to other devices associated with other access points attached to the cable TV network.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: November 22, 2016
    Inventor: David R. Elmaleh
  • Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
    Publication number: 20160310503
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Application
    Filed: February 19, 2016
    Publication date: October 27, 2016
    Inventor: David R. Elmaleh
  • Delivery system for intravascular device with netting
    Patent number: 9452041
    Abstract: In a cardiac double stent having an outer netting over an inner scaffolding, a limiting ridge for defining advancement of the outer netting over the inner scaffolding, and locking clips integrated in the outer netting for engaging the scaffolding at the insertion limit, assures definite placement and avoids shifting or movement from retracting of the delivery device. The delivery device further includes restricting ridges limiting advancement of the inner netting to overlie the inner scaffolding a substantially equal portion on the proximate and distal ends of a guide wire such that balloon catheter expands first at the overlying portion outside the inner scaffolding to sealably contact the lumen wall on each side of the scaffolding to prevent contamination.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: September 27, 2016
    Inventors: David R. Elmaleh, Boyan C. Goumnerov
  • Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
    Publication number: 20160271101
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Application
    Filed: February 18, 2016
    Publication date: September 22, 2016
    Inventor: David R. Elmaleh
  • Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
    Publication number: 20160271138
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Application
    Filed: February 19, 2016
    Publication date: September 22, 2016
    Inventor: David R. Elmaleh
  • Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
    Publication number: 20160271277
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Application
    Filed: February 18, 2016
    Publication date: September 22, 2016
    Inventor: David R. Elmaleh
  • CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT
    Publication number: 20160263257
    Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula; wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, mi-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.
    Type: Application
    Filed: October 22, 2014
    Publication date: September 15, 2016
    Inventors: David R. ELMALEH, Timothy SHOUP
  • Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
    Publication number: 20160166550
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 16, 2016
    Inventor: David R. Elmaleh
  • Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
    Publication number: 20160166534
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 16, 2016
    Inventor: David R. Elmaleh
  • Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
    Publication number: 20160168239
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 16, 2016
    Inventor: David R. Elmaleh
  • Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
    Publication number: 20160158165
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 9, 2016
    Inventor: David R. Elmaleh